Yas Holding to Acquire Stake in Alvotech and Signs an Exclusive Agreement for its Three Biosimilar Candidates

Shots:

Alvotech to receive ~$45M as up front, equity investment, milestone while Yas Holding has acquired a 2.5% stake in Alvotech business and get rights to commercialize Alvotech’s three biosimilar candidates in MENA region
The investment will complement Yas holding an existing portfolio and expands its footprints in health & pharmaceutical sector both in the MENA region and abroad
Additionally, in Nov’2018, Fuji Pharma invest ~$50M for a 4.2% stake in the Alvotech and in Feb’2019 Fujipharma got exclusive rights to commercialize its biosimilar Ustekinumab (referencing Stelara) in Japan

Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire